INTRODUCTION {#s1}
============

Oncogenic mutations in rat sarcoma viral oncogene homolog (*RAS*) genes are detected in approximately 30% of human cancers, predominantly in colorectal cancer, pancreatic cancer, and lung adenocarcinomas \[[@R1]\]. These mutations occur most frequently in Kirsten *RAS* (*KRAS*), which encodes a small GTPase that mediates downstream signaling from growth factor receptors \[[@R2], [@R3]\]. *KRAS* mutations can constructively activate downstream signaling pathways, such as *RAS*/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinases (ERK) and phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), and this signaling pathway activation triggers nuclear gene transcription and cell differentiation and proliferation \[[@R4]\].

However, *KRAS* mutation alone, which occurs in the early process of tumorigenesis, is not sufficient to induce malignant transformation of normal epithelial cells \[[@R5], [@R6]\]. Additional loss of tumor suppressor genes, such as *TP53* \[[@R7], [@R8]\], is required for cancer development, which arises through sequential accumulation of oncogenic mutations and loss of tumor suppressor genes. Somatic *TP53* mutation is the most common genetic aberration in tumor suppressor genes, occurring in 10% to 96% of human cancers \[[@R9]\]. Functional *TP53* mutations lead to ablation of cell cycle arrest and DNA damage repair, as well as overexpression of nuclear target genes, resulting in genomic instability and tumor development \[[@R10]\]. Dual mutations in *TP53* and *KRAS* (*KRAS+*/*TP53+*, + indicates positive hotspot test) occur in up to 20% of advanced solid tumors \[[@R11]--[@R14]\]. In genetically engineered mouse models, mice harboring both the *TP53* R172H and *KRAS* G12D mutations had a significantly shortened latency, and thus more tumors than mice with the *KRAS* G12D mutation alone \[[@R7], [@R15]\].

Because concurrent *KRAS* and *TP53* mutations manifest potentially synergistic biologic effects, cancers carrying both *KRAS* and *TP53* mutations (*KRAS*+/*TP53*+) might represent a unique cancer subtype with distinct and aggressive biologic behaviors \[[@R16]\]. Blockade of downstream signaling pathways such as RAF/MEK or PI3K/AKT/mTOR in *KRAS*-mutant cancer \[[@R17]\] and antiangiogenic-based therapy in *TP53*-mutant cancer would be appropriate therapeutic strategies \[[@R18], [@R19]\]. Unfortunately, effective therapies directly targeting *TP53* or *KRAS* mutations are not available and these mutations are currently considered undruggable \[[@R20], [@R21]\].

Many phase I clinical trials include patients with malignancies arising from undruggable genetic mutations, but it is unclear which types of therapies are most promising for the treatment of these malignancies. Therefore, it is of great scientific interest and clinical urgency to explore potential therapeutic options for malignancies with undruggable genetic mutations. In the current study, we reviewed demographics and clinical outcomes of patients with advanced *KRAS+*/*TP53+* mutant cancers who were referred to phase I clinical trials at The University of Texas MD Anderson Cancer Center. Our aims were to investigate specific genetic aberrations associated with clinical outcomes and to identify potential therapeutic regimens for the treatment of advanced *KRAS+*/*TP53+* mutant cancers.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

From March 2102 to October 2014, 2, 144 consecutive patients with advanced cancers were referred to phase I clinical trials at MD Anderson and underwent molecular tests for tumor genetic aberrations. Among these patients, 167 (7.8%) harbored concurrent *KRAS* and *TP53* hotspot mutations (*KRAS+*/*TP53+* mutant cancer), 182 (8.5%) harbored *KRAS+*/*TP53*-- hotspot mutations, and 839 (39.1%) harbored *KRAS*--/*TP53+* hotspot mutations (- indicates negative hotspot test). Four patients with *KRAS+*/*TP53+* mutant cancer had insufficient clinical data and were not included in our analysis. The baseline characteristics of the remaining 163 patients are summarized in Table [1](#T1){ref-type="table"}.

###### Patient baseline characteristics (n=163)

  Characteristics                     Patient number   Percentage (%)
  ----------------------------------- ---------------- ----------------
  Age (median, range)                 55 (17-83)       
  Gender                                               
   Male                               97               60
   Female                             66               40
  Race                                                 
   White                              103              63
   African American                   25               15
   Hispanic                           23               14
   Asian                              4                3
   Others                             8                5
  Type of cancer                                       
   Colorectal                         104              64
   Pancreatic                         28               17
   Lung\*                             8                5
   Others\*\*                         23               14
  With second primary cancer                           
   Yes                                20               12
   No                                 143              88
  Sites of metastasis                                  
   Lung                               116              71
   Liver                              113              69
   Lymph node                         61               37
   Peritoneal                         37               23
   Bone                               23               14
   Retroperitoneal                    20               12
   Adrenal                            17               10
   Soft tissue                        12               7
   Brain                              8                5
   Cutaneous                          7                4
   Renal                              6                4
   Spleen                             6                4
   Ovarian                            4                2
   Vaginal                            4                2
  Initial diagnosis with metastasis                    
   Yes                                89               55
   No                                 74               45

^\*^Lung cancers included adenocarcinoma (n=5), adenosquamous (n=2) and neuroendocrine (n=1). \*\*Other cancers included cholangiocarcinoma (n=3), esophageal (n=1), gastric (n=1), duodenal (n=1), uterine (n=4), ovarian (2), vaginal (n=1), bladder (n=1), sinonasal (n=1), thyroid (n=1), appendiceal (n=2), skin squamous (n=1) and cancer of unknown primary (n=4).

Molecular aberrations {#s2_2}
---------------------

In the 163 patients with *KRAS+*/*TP53+* mutant cancer, G12 (n = 107; 66%) and G13 (n = 25; 15%) mutations constituted the majority of *KRAS* hotspot mutations. In patients with pancreatic cancers, G12 mutations occurred more frequently (*p* = 0.003), but G13 mutations were not found. In the total cohort of patients (n = 163), 83 types of *TP53* mutations were found, of which 44% were common hotspot mutations: R273 (n = 26; 16%), R175 (n = 19; 12%), R248 (n = 12; 7%), G245 (n = 9; 6%), and R282 (n = 5; 3%). Association of a *TP53* hotspot mutation with a specific cancer was not observed. Other concurrent genetic aberrations were found in most patients (n = 125; 77%), and more than one concomitant genetic aberration was found in 87 patients (53%): *APC* (n = 65; 40%), *PIK3CA* (n = 37; 23%), *KIT* (n = 34; 21%), *SMAD4* (n = 18; 11%), *FBXW7* (n = 11; 7%), *MET* (n = 10; 6%), *JAK3* (n = 9; 6%), *CDKN2A* (n = 9; 6%), *PTEN* (n = 6; 4%), and *STK11* (n = 5; 3%).

Antitumor activity and PFS {#s2_3}
--------------------------

Approximately one-third of patients (n = 57) received a total of 78 phase I trial therapies under 50 different phase I clinical trials. These therapies yielded 2 PRs and 17 SDs (24% of disease control), associated with a median PFS of 2.1 months (95% confidence interval \[CI\] 1.8-2.4). Among patients treated with an antiangiogenic agent (n = 15), 11 (73%) had PR or SD and the median PFS was 3.7 months (95% CI 2.8-4.6), which was significantly better than among patients who were not treated with an antiangiogenic agent (8/39 \[21%\] PR or SD, *p* \< 0.001; PFS 1.8 months \[95% CI 1.6-2.0\], *p* = 0.043). In patients who received therapies with one agent targeting a concomitant genetic aberration or its downstream proteins (gene aberration-related therapy), the disease control rate was 65% (17/26) and the median PFS was 3.7 months (95% CI 2.6-4.8), which was significantly better than among patients who did not receive this type of treatment (2/28 \[7%\] PR or SD, *p* \< 0.001; PFS 1.6 months \[95% CI 1.2-2.0\], *p* \< 0.001). In patients receiving gene aberration-related phase I clinical trial therapy, PFS was similar to that observed with previous standard of care therapy before phase I clinical trial referral (2.5 months \[95% CI 1.4-3.6\], *p* = 0.866).

Overall survival {#s2_4}
----------------

A median OS of 6.7 months (95% CI 4.9-8.5) was observed in the 163 patients with *KRAS+*/*TP53+* mutant cancer who were referred to phase I clinical trials at MD Anderson. Patients who received therapy in a phase I clinical trial had a median OS of 12 months (95% CI 5.6-18.4), which was significantly better than the median OS in those who did not (4.6 months \[95% CI 3.6-5.6\], *p* = 0.003). Patients receiving phase I clinical trial therapies with an antiangiogenic agent had a median OS of 13.4 months (95% CI 5.5-20.2), and those receiving gene aberration-related phase I clinical trial therapies had a median OS of 13.5 months (95% CI 5.3-20.6). These OS times compared favorably with those of patients who did not receive these treatments (no antiangiogenic therapy: median OS 8.8 months \[95% CI 3.0-14.6\], *p* = 0.6; and no gene aberration-related phase I clinical trial therapy: median OS 7.6 months \[95% CI 7.1-8.1\], *p* = 0.2) respectively.

Association of OS with genetic aberrations {#s2_5}
------------------------------------------

Further analysis in 163 patients with *KRAS+*/*TP53+* mutant cancer revealed that patients harboring G13 mutations (n = 25) had a median OS of 4.8 months (95% CI 2.5-7.1), which was significantly worse than among those without the G13 mutation (n = 138, median OS 7.3 months \[95% CI 4.8-9.8\], *p* = 0.016). No survival difference was observed between patients with G12 mutations and those without. In patients with colorectal cancers, G13 mutations remained associated with reduced OS (n = 22, median OS 4.8 months \[95% CI 2.5-7.1\]) compared with patients without G13 mutations (n = 82, median OS 8.4 months \[95% CI 5.3-11.5\]; *p* = 0.012), as shown in Figure [1](#F1){ref-type="fig"}. Patients with a *TP53* R273 mutation (n = 14) had a median OS of 5.7 months \[95% CI 3.0-8.4\], which was worse than in patients without the R273 mutation (n = 90, median OS 8.5 months \[95% CI 5.8-11.2\]; *p* = 0.048), as shown in Figure [2](#F2){ref-type="fig"}.

![Kaplan-Meier overall survival (OS) curves in patients with *KRAS+*/*TP53+* mutant colorectal cancer who received therapy in a phase I clinical trial, stratified by *KRAS* G13 mutation status (due to sample size, all p values are unadjusted)\
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![Kaplan-Meier overall survival (OS) curves in patients with *KRAS+*/*TP53+* mutant colorectal cancer who received therapy in a phase I clinical trial, stratified by *TP53* R273 mutation status (due to sample size, all p values are unadjusted)\
.](oncotarget-08-33796-g002){#F2}

Exploratory study of a prognostic model {#s2_6}
---------------------------------------

We were unable to apply the Royal Marsden Hospital score \[[@R22]\] or the MD Anderson prognostic score \[[@R23]\] to the 57 patients who received therapy in a phase I clinical trial. Therefore, we decided to explore a prognostic model specific to patients with *KRAS+*/*TP53+* mutant cancer. First, we analyzed the association of OS with potential risk factors using univariate and multivariate analyses in these 57 patients (Table [2](#T2){ref-type="table"}). Five independent poor risk factors were identified for predicting individual survival outcome: neutrophilia, thrombocytosis, hypoalbuminemia, body mass index \<30 kg/m^2^, and the absence of lung metastasis. These parameters were then extracted using binary subgroups (no = 0, yes = 1) to explore a risk prognostic model predictive of OS after the initial phase I clinical trial visit. This model classified the patients into one of two risk cohorts (*p* \< 0.001; Figure [3](#F3){ref-type="fig"}): a low-risk group (score ≤ 1, n = 40) associated with a median OS of 16.6 months (95% CI 12.9-20.4) or a high-risk group (score \> 1, n = 17) associated with a median OS of 5.4 months (95% CI 3.7-7.1).

###### Univariate and multivariate analyses of OS in 57 patients who received a phase I trial therapy

  Potential Risk Factors                                              Patient Number   Median OS (months, 95% CI)   *p* value     
  ------------------------------------------------------------------- ---------------- ---------------------------- ------------- -------------
  Age \< 65 years                                                     Yes (n=46)       10.1 (5.2-15)                0.121         0.185
                                                                      No (n=11)        17.9 (6.7-29.1)                            
  Male                                                                Yes (n=37)       15.2 (6.3-24.1)              0.334         0.228
                                                                      No (n=20)        12 (4.1-19.9)                              
  Colorectal cancer                                                   Yes (n=39)       12 (6.6-17.4)                0.773         0.582
                                                                      No (n=18)        7.3 (0-16.5                                
  Presence of a second primary cancer                                 Yes (n=5)        10.1 (0, infinity)           0.086         0.106
                                                                      No (n=52)        13 (4.6-21.4)                              
  Metastasis at initial diagnosis                                     Yes (n=28)       7.3 (4.2-10.4)               0.176         0.978
                                                                      No (n=29)        13 (8-18.1)                                
  Number of metastatic sites≤ 2                                       Yes (n=18)       13 (2.1-23.9)                0.572         0.402
                                                                      No (n=39)        10.1 (4.2-16)                              
  Lung metastasis                                                     Yes (n=43)       15.4 (8.3-22.5)              **0.015**     **0.01**
                                                                      No (n=14)        7.3 (4.5-10.1)                             
  Liver metastasis                                                    Yes (n=41)       8.5 (4.6-12.4)               0.571         0.593
                                                                      No (n=16)        15.2 (7-23.4)                              
  Eastern Cooperative Oncology Group (ECOG) performance status of 0   Yes (n=8)        16.6 (3.1-30.1)              0.077         0.66
                                                                      No (n=49)        10.1 (3.1-17.1)                            
  Neutrophilia                                                        Yes (n=6)        3.4 (2-4.8)                  **\<0.001**   **\<0.001**
                                                                      No (n=51)        13 (6.6-19.4)                              
  Lymphopenia                                                         Yes (n=16)       7.3 (1.9-12.7)               0.103         0.386
                                                                      No (n=41)        13 (7.4-18.6)                              
  Anemia                                                              Yes (n=41)       13 (4.8-21.2)                0.778         0.097
                                                                      No (n=16)        10.1 (3.9-16.3)                            
  Thrombocytosis                                                      Yes (n=1)        2.6 (0, infinity)            **\<0.001**   **0.022**
                                                                      No (n=56)        12 (5.5-18.5)                              
  Normal lactate dehydrogenase                                        Yes (n=33)       15.2 (11.3-19.1)             0.11          0.119
                                                                      No (n=24)        6.5 (5-8)                                  
  Hypoalbuminemia                                                     Yes (n=2)        2.5 (0, infinity)            **0.016**     **0.029**
                                                                      No (n=55)        13 (6.2-19.8)                              
  Normal creatinine                                                   Yes (n=56)       12 (5.6-18.4)                0.811         0.984
                                                                      No (n=1)         2.7 (0, infinity)                          
  Hyperbilirubinemia                                                  Yes (n=11)       10.1 (4.5-15.7)              0.86          0.039
                                                                      No (n=46)        12 (4.2-20)                                
  Venous thromboembolism                                              Yes (n=12)       12 (3.6-20.4)                0.593         0.281
                                                                      No (n=45)        13 (6.8-19.2)                              
  Body mass index (BMI) ≥30 kg/m^2^                                   Yes (n=11)       12 (0-26.9)                  **0.05**      **0.023**
                                                                      No (n=46)        10.1 (4.2-16)                              

![A prognostic model was established from 57 patients with advanced *KRAS+*/*TP53+* mutant cancer who received therapy in a phase I clinical trial\
Kaplan-Meier overall survival (OS) curves are shown, stratified by risk score (low-risk group: score ≤1, high-risk group: score \>1) (due to sample size, all p values are unadjusted).](oncotarget-08-33796-g003){#F3}

To support this model, we used another cohort of patients who were referred to a phase I clinical trial but did not receive the therapy. In this cohort, patients in the low-risk group (n = 56) had a median OS of 6.7 months (95% CI 3.4-10.0), which was significantly better than that of those in the high-risk group (n = 48, median OS 3.6 months \[95% CI 2.4-4.8\], *p* = 0.033), as shown in Figure [4](#F4){ref-type="fig"}.

![The established prognostic model was validated in 104 patients with advanced *KRAS+*/*TP53+* mutant cancer who did not receive therapy in a phase I clinical trial\
Kaplan-Meier overall survival (OS) curves are shown, stratified by risk score (low-risk group: score ≤1, high-risk group: score \>1) (due to sample size, all p values are unadjusted).](oncotarget-08-33796-g004){#F4}

DISCUSSION {#s3}
==========

Our findings suggest that the *KRAS* G13 and *TP53* R273 mutations are associated with poor outcome in patients with *KRAS*+/*TP53*+ mutant cancer, and antiangiogenic therapy combined with therapy targeting specific genetic aberrations may be an effective treatment strategy. To the best of our knowledge, the current study is the first to analyze clinical outcomes of patients with advanced hotspot *KRAS+*/*TP53+* mutant cancers who were referred to a phase I clinical trial program at MD Anderson.

*KRAS* and *TP53* are frequently mutated in many types of cancer. Although they are highly attractive therapeutic targets, they remain outside of the reach of direct pharmacologic intervention \[[@R20]\]. Until a breakthrough is achieved with a direct pharmacologic approach, alternative strategies for addressing these undruggable targets remain under investigation \[[@R24]\]. Unfortunately, we found that only approximately one-third of patients with advanced hotspot *KRAS+*/*TP53+* mutant cancers received treatment in a phase I clinical trial, much less than the overall rate of 55% of all patients who were referred to phase I clinical trials at the same institution \[[@R25]\].

A median OS of 12 months was observed in patients with *KRAS+*/*TP53+* mutant cancer who had received treatment in a phase I clinical trial, consistent with a previous study showing a median OS of 10 months in 1,181 consecutive cancer patients treated in phase I clinical trials \[[@R23]\]. Other studies have reported a median OS of 8 months in 365 patients harboring hotspot *KRAS* mutations \[[@R13]\] and 14.6 months in 188 patients harboring hotspot *TP53* mutations at the same institution \[[@R14]\]. These findings indicate that outcomes for patients with hotspot *KRAS+*/*TP53+* mutant cancer who enroll in phase I clinical trials are better than in those with hotspot *KRAS* mutations \[[@R13]\] but worse than in those with hotspot *TP53* mutations \[[@R14]\]. The differential outcomes for patients with specific cancer genetics \[[@R26]\] may reflect the reality that there are many phase I clinical trials of antiangiogenic-based therapeutic regimens but few studies appropriate for those with hotspot *KRAS* mutations \[[@R25]\]. These findings also suggest that patients harboring hotspot *TP53* mutations may benefit from antiangiogenic-based therapeutic regimens \[[@R19]\]. The evidence that the Royal Marsden Hospital score or the MD Anderson prognostic score could not be used to predict outcomes of the patients with KRAS+/TP53+ mutant cancer who received a phase I clinical trial therapy may indicate that the outcome was related to their unique biological characteristics, and availability of effective phase I trial therapy.

In our cohort of patients with *KRAS+*/*TP53+* mutant cancer, approximately two-thirds of patients had *KRAS* G12 mutations and one-sixth had G13 mutations. Although the absence of a G13 mutation is usually associated with poor prognosis in pancreatic cancer, the presence of a G13 mutation was associated with significantly shorter OS than other *KRAS* mutations in our full cohort of patients with *KRAS+*/*TP53+* mutations and in those with colorectal cancer. This is consistent with previous findings showing that the *KRAS* G13 mutation was an independent prognostic factor for poor metastasis-free survival in colon cancer compared with either wild-type *KRAS* or G12 mutation \[[@R27], [@R28]\].

We observed a total of 83 types of *TP53* mutations in our cohort, and most were located in the DNA binding domain. In contrast with a previous study showing that patients with hotspot *TP53* R273 mutant ovarian cancer had significantly longer median OS than those with other hotspot *TP53* mutations \[[@R29]\], our study revealed that a hotspot *TP53* R273 mutation was associated with poor survival in patients with metastatic colorectal cancer. These inconsistent data imply that different cell contexts may lead to different outcomes, which warrants further investigation clinically and preclinically.

Although genetics likely play an important role in tumorigenesis, the inflammatory process is initiated by the movement of innate immune system cells to the microenvironment, followed by the secretion of proinflammatory cytokines, growth factors, and reactive oxygen species, causing DNA damage and promoting neoplastic development, as has been found in many tumor types \[[@R6]\]. Our multivariable analysis revealed that five independent baseline factors (neutrophilia, thrombocytosis, hypoalbuminemia, body mass index \<30 kg/m^2^, and the absence of lung metastasis) were able to predict individual outcome not only in patients with *KRAS+*/*TP53+* mutant cancer who had received therapy in a phase I clinical trial, but also in those who had not received therapy. Four of these prognostic factors are related to the proinflammatory state, which works alongside *KRAS* and *TP53* mutations to enhance tumor progression and develop resistance to cancer therapy, resulting in poor clinical outcomes \[[@R30]--[@R32]\]. Therefore, a thorough understanding of the mechanisms of the proinflammatory state in conjunction with cancer-related gene aberrations may provide a scientific rationale to develop effective therapeutic strategies for advanced *KRAS+*/*TP53+* mutant cancer. Though we cannot completely explain association of the absence of lung metastasis with poor outcome, we did observe that phase I metastatic colorectal cancer patients with pulmonary metastasis had a relatively slow process for tumor progression, which might reflect different biologic properties of these tumors, and requires further investigation.

Our study has limitations. First, the retrospective setup and limited sample size might yield statistical bias. Due to multiplicity of statistical testing in such small sample size, all *p* values are exploratory and unadjusted. Second, data from patients with hotspot *KRAS+*/*TP53*-, *KRAS*-/*TP53+*, and *KRAS*-/*TP53*- cancer were not available for our analysis of patients with metastatic *KRAS+*/*TP53+* mutant cancer, which limited our ability to reach conclusions from data comparison among these four groups of patients.

PATIENTS AND METHODS {#s4}
====================

Patients {#s4_1}
--------

We retrospectively reviewed 2,144 consecutive patients with advanced cancers who were referred to phase I clinical trials at MD Anderson from March 2102 to October 2014 and who had sufficient tumor tissue specimens available for next generation sequencing. Among these patients, 167 harbored concurrent hotspot mutations in the *KRAS* and *TP53* genes. Patient baseline demographics, laboratory results, gene aberrations, status of phase I clinical trial therapy, and clinical outcomes were obtained from electronic medical records. All patients were followed until death or censored on March 10, 2016. Trial conduct, data collection, and subsequent data analysis were performed in accordance with the guidelines of the MD Anderson Institutional Review Board (IRB) after the IRB approval for the research and a waiver of informed consent were obtained.

Molecular analysis {#s4_2}
------------------

For somatic hotspot mutation analysis, DNA was extracted, purified, and quantified from microdissected, paraffin-embedded tumor specimens. Next generation sequencing for hotspot mutations was performed using the Ion Ampliseq Cancer Panel (Life Technologies, Grand Island, NY) in a Clinical Laboratory Improvement Amendments-certified Molecular Diagnostics Laboratory at MD Anderson \[[@R19], [@R33]\]. A panel of 46 genes was initially tested and then expanded to 50 genes, as described previously \[[@R34]\].

Treatment and evaluation {#s4_3}
------------------------

The decision to enroll an eligible patient in a phase I clinical trial depended on the protocol availability and the discretion of the treating physicians. Tumor responses (CR = complete remission, PR = partial response, SD = stable disease, and PD = progressive disease) were evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 or 1.1 \[[@R35], [@R36]\], depending on individual protocols. Progression-free survival (PFS) was calculated from the date of initiation of a phase I clinical trial therapy to the date of first objective documentation of PD, death, or censor date. PFS for patients alive and progression-free at last evaluation should be censored at date of last clinical evaluation. Overall survival (OS) was calculated from the date of the initial phase I clinical trial visit to the date of death or censor date. Time to death for patients alive at last contact should be censored at date of last contact.

Statistical analysis {#s4_4}
--------------------

Continuous interval-scaled data were summarized as median (range). Categorical data were summarized as frequencies and relative frequencies. Associations between categorical variables were tested using the chi-squared and Fisher exact tests. PFS and OS curves were estimated using the Kaplan-Meier method and compared using log rank tests. Cox proportional hazards regression analysis was used for multivariable analysis. All tests were two-sided and considered significant when p \< 0.05. Analyses were performed using SPSS version 23.0 (SPSS, Chicago, IL).

CONCLUSIONS {#s5}
===========

We found that hotspot *KRAS+*/*TP53+* mutations occurred in approximately 8% of cancer patients referred to our institution for phase I clinical trials, and that the *KRAS* G13 mutation, as well as the *TP53* R273 mutation, were associated with poor OS. Antiangiogenesis and gene aberration-related therapies may improve overall survival in patients with concurrent *KRAS+*/*TP53+* hotspot mutant cancer. Also our data also suggest that the proinflammatory state is a key event in cancer development, facilitated through evolving gene aberrations. The current study has provided further support that the combination of modulating the proinflammatory state via immunotherapeutic agents \[[@R37]\] with expanding pharmacologic manipulation to address undruggable molecular cancer targets may lead to novel and effective approaches to the treatment of *KRAS+*/*TP53+* mutant advanced cancer.
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